



## Advancing Clinical Decision-Making in ATTR-CM

Posted April 6, 2026

### I. BACKGROUND

Alnylam Pharmaceuticals, Inc. (Alnylam) is committed to supporting innovative, independent projects that address unmet educational needs and are intended to improve outcomes in the patient communities that Alnylam serves.

Alnylam publicly posts Requests for Proposals (RFP) that are focused on a specific area of interest and establishes timelines and other requirements for receipt and review. All proposals are the sole responsibility of the requesting organization, and Alnylam has no influence over any aspect of the project.

NOTE: The RFP process is separate from the Alnylam review and approval pathway for investigator-initiated studies (IIS). To submit an IIS request, please refer to <https://www.alnylam.com/about-alnylam/investigator-initiated-studies/>.

All organizations carrying out Alnylam-supported projects must adhere to the below terms and conditions as well as relevant laws, codes, and regulations.

### II. ELIGIBILITY

<b>Applicant Eligibility</b>	<p>Professional associations, patient advocacy organizations, healthcare institutions, medical education companies and other organizations committed to healthcare improvement may apply.</p> <p>Individuals (such as individual healthcare providers), healthcare provider practice groups, healthcare provider-owned clinics, managed care organizations, and pharmacy benefit managers are prohibited from applying for this grant.</p> <p>Medical education providers must be Accreditation Council for Continuing Medical Education (ACCME)-accredited, and the requestor must be the accredited provider.</p>
------------------------------	---

### III. SCOPE

<b>RFP Number</b> <i>(include on all documents)</i>	ALNY-RFP-TTR-13
<b>Issue Date</b>	April 6, 2026
<b>Submission Deadline</b>	May 29, 2026
<b>Notification Date</b>	June 12, 2026
<b>Therapeutic Area</b>	Transthyretin-mediated Amyloidosis (ATTR amyloidosis)

## Educational Focus

Educational activities should address persistent gaps in the screening, diagnosis, monitoring, and management of ATTR, with a primary emphasis on practical, real-world clinical decision-making and application in routine practice across the patient journey.

Proposals should focus on equipping clinicians with actionable information, insights, tools, and frameworks that can be readily implemented at the point of care.

Priority areas include:

- **Disease biology, pathophysiology, mechanism of disease in context of mechanisms of action of therapies** – translated into clinically relevant implications for clinical-decision making
- **Screening, early diagnosis, and risk identification** - emphasizing practical and feasible approaches to recognizing red flags and integrating screening into everyday workflows
- **Early treatment** - emphasizing the importance of timely intervention and interpretation of clinical trial subgroup data (i.e., by NYHA class) to inform treatment decisions and optimize patient outcomes
- **Long-term evidence** - emphasizing how to interpret and apply longitudinal data from ongoing open-label phases of pivotal studies in ongoing patient management
- **Evidence of amyloid clearance and/or disease modification and regression** – interpretation of existing data as well as generation of new data on amyloid clearance, disease modification (including disease regression)
- **Imaging** - emphasizing disease pathophysiology and the application and interpretation of imaging-derived evidence from clinical trials
- **Emerging therapy selection considerations** - including real-world considerations such as cardiac and extra-cardiac manifestations, drug–drug interactions, treatment burden, adherence, persistence and polypharmacy considerations.
- **Real-world clinical experience** - including real case-based learning that reflects both common and complex patient scenarios
- **Disease monitoring, assessment of disease progression and therapy optimization** - including practical frameworks to guide reassessment and treatment decisions over time
- **Multidisciplinary care approaches** – highlighting practical coordination across specialties, center of excellences model, referral pathways in routine clinical practice

Educational content should be grounded in **established, peer-reviewed evidence** and designed to support **practical clinical application and informed decision-making in a fair and balanced way.**

**Program should also provide where appropriate:**

- Pre- and post-assessments of program efficacy
- Enduring accessibility (hosted or links) to references and associated clinical materials (algorithms, guidelines, etc.)

	<ul style="list-style-type: none"> <li>Publicly accessible, HCP-gated, work-product (i.e., comprehensive PowerPoint slides, videos, etc.) for use by HCPs in building other independent (non-accredited) educational programs</li> </ul>
<b>Preferred Launch Date for Educational Content</b>	August 2026
<b>Geographic Scope</b>	U.S. and/or Global
<b>Target Audience</b>	<p>Specialists that may manage ATTR-CM or have an interest in the disease including:</p> <ul style="list-style-type: none"> <li>Cardiologists, -including but not limited to- nuclear cardiologists, echocardiographers, cardiac imaging specialists, interventional cardiologists, heart failure specialists, or cardiology nurse practitioners</li> <li>Clinical pharmacists with a focus on cardiology</li> </ul> <p><b>Note:</b> Proposals do not necessarily need to target all audience segments; educational focus should be tailored to the venue, channel, and the specific HCP audience’s role, geography (including the restrictions and requirements of the relevant country laws, regulations, and codes), gaps, and needs assessment.</p>
<b>Target Channel</b>	<p>Proposals will be reviewed based on the following venues/channels:</p> <ol style="list-style-type: none"> <li>Fall 2026 Cardiology Congresses Symposia (i.e., <b>ESC, ASNC, HFSA</b> and/or <b>AHA</b>)</li> <li>Major Clinical Pharmacy Symposia at fall congresses</li> <li>National (US) or Global Digital Continuing Medical Education Platforms</li> <li>Regional (US) Live Programs across multiple geographic areas, as well as <b>key regional/national congresses outside of US</b></li> </ol> <p>Proposals should consider <b>region-specific channels and digital platforms</b> to optimize reach and relevance across geographies.</p>
<b>Funding Budget</b>	<p>Individual proposals may be awarded up to <b>\$250,000 USD</b>. The amount of the grant funded may vary from the amount requested. Therefore, Alnylam encourages submission of grant requests with multiple sources of funding support, including registration fees or other funding allocations.</p> <p><b>Note:</b> Multiple proposals may be awarded (i.e., for symposia at different cardiology congresses). Applicants wishing to propose educational activities across multiple venues or channels should either submit separate proposals or clearly delineate budgets, learning objectives, and target audiences within a single submission. In cases where multiple venues or channels are proposed, Alnylam reserves the right to fund discrete events rather than the full proposal.</p>

#### IV. Proposal Guidelines

<b>Gap Analysis/Needs Assessment</b>	Include a comprehensive gap analysis/needs assessment that is well referenced and adequately establishes that the program is needed to benefit patient care, knowledge, or other public health objectives.
--------------------------------------	--

	Identify any potential barriers to healthcare professional (HCP) practice change and how these barriers will be addressed within the educational initiative.
<b>Target Audience</b>	Describe the target audience(s) and provide a rationale for why this target audience(s) is important to closing the identified healthcare gap.
<b>Audience Recruitment</b>	Describe the methods for reaching the target audience(s), including a description of recruitment and placement strategies to maximize participation based on need.
<b>Learning Objectives</b>	Provide clearly defined, SMART (specific, measurable, achievable, relevant, timely) learning objectives for learners as a result of attending this activity.
<b>Content Accuracy</b>	<p>Include an overview of program content and explanation of criteria that will guide content selection.</p> <p>Design the activity so that it is free of commercial bias for or against any product; any product discussions are objective, balanced, and scientifically sound; and any discussion of uses of a drug that have not been approved by the FDA are identified as such.</p> <p>Explain how content will be updated, if necessary, throughout the activity period and how accuracy will be ensured.</p>
<b>Educational Design</b>	<p>Proposed educational methods should be selected based on the professional practice gaps and educational needs of the target audience(s).</p> <p>Educational format must be interactive and consider appropriate target audience and learning preferences. Use of technology to enhance learner engagement, reinforcement, and retention is encouraged.</p>
<b>Faculty Recruitment</b>	Provide information on the expected qualifications of contributors and description of methods to ensure recruitment of course directors and faculty who meet the qualifications.
<b>Activity Evaluation and Outcomes Reporting</b>	Provide a description of how the activity will be evaluated against objectives and reported.
<b>Budget</b>	<p>Include a detailed budget, with a breakdown of costs for each line item, clear explanation of the units, and how Alnylam funds will be allocated for each of the line items.</p> <p>Budget costs should be reasonable and customary, within fair market value, and proportionate to the type and length of activity. Grant funds may not be used for meals for attendee HCPs.</p>
<b>Accreditation</b>	<p>Provide proof of accreditation status in good standing.</p> <p>Activities must be accredited by the appropriate accrediting bodies (i.e., ACCME) and fully compliant with all standards and criteria, including the ACCME Standards for Integrity and Independence in Accredited Continuing Education. If the activity is jointly provided, the accredited provider must be involved from the concept origin and fully knowledgeable of all contents of the grant submission, and documentation should be provided on the relationship between the accredited provider and non-accredited educational partner.</p>
<b>Identification and Resolution of Conflicts of Interest</b>	Describe methods for ensuring fair and balanced content, identification and resolution of conflicts of interest, and how the activity will remain free from commercial bias.

<b>Disclosure</b>	Include a description of how the provider a) discloses relevant financial relationships for all individuals in control of content, and b) discloses educational grant support for this activity.
<b>Sustainability</b>	Describe specific plans to broadly disseminate the proposed activity's results and ensure sustainability beyond the funding program.
<b>Honoraria Policy</b>	Provide documentation that describes the honoraria and reimbursement policies.
<b>Project Timeline</b>	Provide a detailed timeline that includes but is not limited to dates for development, launch, interim report, and final report.

## V. DIRECTIONS FOR SUBMISSION

<b>Submissions</b>	Requests must be submitted through Alnylam's grant portal <a href="https://alnylam-grants.steeproclinc.com">https://alnylam-grants.steeproclinc.com</a> or through Alnylam's corporate website: <a href="https://www.alnylam.com/about-alnylam/grants-and-giving">https://www.alnylam.com/about-alnylam/grants-and-giving</a>
<b>Contact Information</b>	Direct questions about this RFP to <a href="mailto:grants@alnylam.com">grants@alnylam.com</a>
<b>Notification</b>	All applicants will be notified by email of a decision.

## VI. TERMS AND CONDITIONS

1. Alnylam may request supplemental information from applicants, and Alnylam reserves the right to reject incomplete applications.
2. This RFP does not commit Alnylam or its affiliates to award a grant of any size, nor to pay any costs incurred in the preparation of a response to this request. Alnylam reserves the right not to fund any request. No grant has been awarded until a formal grant agreement has been fully executed between Alnylam and the applicant organization(s).
3. Alnylam reserves the right to accept or reject any or all applications received as a result of this request, or to cancel this RFP in part or in its entirety.
4. Alnylam adheres to all applicable transparency laws, codes, and regulations, and, as a result, will appropriately report funding related to this grant, when and as required.
5. Alnylam may require receipt of required information in a certain format from recipient organization(s) in order to facilitate disclosure reporting.
6. Alnylam reserves the right to verify all information provided by an organization in its grant application.
7. Only the Alnylam Grants and Giving Office is authorized to provide information related to this RFP. Please contact the office at [grants@alnylam.com](mailto:grants@alnylam.com).